Sign up
Log in
CNS Pharmaceuticals prices $22.5 million private placement at $2.30 per share
Share
Listen to the news
CNS Pharmaceuticals prices $22.5 million private placement at $2.30 per share
  • CNS Pharmaceuticals entered securities purchase agreements for an oversubscribed private placement expected to raise about USD 22.5 million in gross proceeds.
  • Financing includes sale of 650,000 common shares at USD 2.3 per share, pre-funded warrants to buy 9,143,479 common shares at USD 2.299 per warrant.
  • Pre-funded warrants carry an exercise price of USD 0.001 per share; closing expected around May 5, 2026.
  • Proceeds earmarked for acquiring clinical-stage assets with near-term catalysts, working capital, general corporate purposes; company also pursuing out-licensing of legacy Berubicin and TPI-287 programs.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CNS Pharmaceuticals Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202605040700ACCESSWRNAPR_____1163368) on May 04, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
Terms of Service·Privacy Policy·Data Disclaimer
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved